Results 251 to 260 of about 1,389,226 (316)

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata   +10 more
wiley   +1 more source

Local immunosuppressive microenvironment underlies reduced responsiveness to imiquimod treatment in recurrent or residual cervical HSIL. [PDF]

open access: yesGynecol Oncol Rep
Muntinga CLP   +8 more
europepmc   +1 more source

Methods of measuring residual stresses in components [PDF]

open access: yesMaterials & Design, 2012
Residual stresses occur in many manufactured structures and components. Large number of investigations have been carried out to study this phenomenon and its effect on the mechanical characteristics of these components.
Michele Dassisti   +2 more
exaly   +2 more sources

Home - About - Disclaimer - Privacy